Literature DB >> 15451571

Activin, inhibin and the human breast.

F M Reis1, S Luisi, M M Carneiro, L Cobellis, M Federico, A F Camargos, F Petraglia.   

Abstract

Activins and inhibins are growth factors involved in cell differentiation and proliferation. Human breast tissues such as normal mammary tissue, fibroadenoma, and breast cancer express inhibin and activin mRNA and proteins. Activin A and its binding protein, follistatin, are also present in human milk during the first week of lactation. Using immunohistochemistry, we have observed that the inhibin/activin alpha, betaA, and betaB subunits are present in normal breast tissue regardless of menstrual cycle phase or menopause, as well as in fibrocystic disease, and breast tumors. The mRNAs encoding all three activin/inhibin subunits are expressed in breast carcinoma, fibroadenoma, and normal mammary tissue. The betaA subunit gene expression is higher in either local or metastatic breast carcinoma than in normal tissue. In addition, dimeric activin A is detectable in homogenates of breast cancer tissue at concentrations twice as high as in non-neoplastic adjoining tissue. Recent evidence suggests that some of the activin A produced by breast carcinoma is released into systemic circulation. In women with breast cancer, serum activin A levels are often elevated, and a significant decrease is observed in the first and second days following tumor excision. The role of activin and inhibin as endocrine and/or paracrine factors in the breast is still uncertain. Activin has complex effects on cell growth during branching morphogenesis, but it is generally considered as an inhibitor of cell proliferation as in vitro studies have shown that activin A treatment of breast cancer cells arrests cell growth. Inhibin is generally considered as a tumor suppressor, but its possible role in the breast is less understood.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15451571     DOI: 10.1016/j.mce.2004.02.016

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  24 in total

1.  microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis.

Authors:  Aaron E Hoffman; Tongzhang Zheng; Chunhui Yi; Derek Leaderer; Joanne Weidhaas; Frank Slack; Yawei Zhang; Trupti Paranjape; Yong Zhu
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

Review 2.  The role of activin in mammary gland development and oncogenesis.

Authors:  Karen A Dunphy; Alan L Schneyer; Mary J Hagen; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-08       Impact factor: 2.673

Review 3.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

4.  DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions.

Authors:  Colleen Fordyce; Tim Fessenden; Curtis Pickering; Jason Jung; Veena Singla; Hal Berman; Thea Tlsty
Journal:  Cancer Prev Res (Phila)       Date:  2009-12-22

5.  Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.

Authors:  Fancai Zeng; Guoxiong Xu; Tiejun Zhou; Chengwan Yang; Xinyan Wang; Chun Peng; Hong Zhou
Journal:  Med Oncol       Date:  2011-11-16       Impact factor: 3.064

6.  Testes-specific protease 50 promotes cell proliferation via inhibiting activin signaling.

Authors:  Z-B Song; P Wu; J-S Ni; T Liu; C Fan; Y-L Bao; Y Wu; L-G Sun; C-L Yu; Y-X Huang; Y-X Li
Journal:  Oncogene       Date:  2017-06-26       Impact factor: 9.867

7.  The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells.

Authors:  D Yoshida; K Koketshu; R Nomura; A Teramoto
Journal:  J Neurooncol       Date:  2010-03-23       Impact factor: 4.130

Review 8.  The Activin Social Network: Activin, Inhibin, and Follistatin in Breast Development and Cancer.

Authors:  Darcie D Seachrist; Ruth A Keri
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

9.  The immunoexpressions and prognostic significance of inhibin alpha and beta human chorionic gonadotrophins (HCG) in breast carcinomas.

Authors:  Eundeok Chang; Eunjung Lee; Se Jeong Oh; Jeong Soo Kim; Changsuk Kang
Journal:  Cancer Res Treat       Date:  2005-08-31       Impact factor: 4.679

10.  Differential expression of follistatin and FLRG in human breast proliferative disorders.

Authors:  Enrrico Bloise; Henrique L Couto; Lauretta Massai; Pasquapina Ciarmela; Marzia Mencarelli; Lavinia E Borges; Michela Muscettola; Giovanni Grasso; Vania F Amaral; Geovanni D Cassali; Felice Petraglia; Fernando M Reis
Journal:  BMC Cancer       Date:  2009-09-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.